



April 8, 2022.

Dear all,

Company name: SUNCORPORATION  
Name of representative: Ryusuke Utsumi,  
CEO  
(Code No. 6736 TSE Standard)  
Contact: Yoshimi Kimura,  
Senior Managing Director  
(Tel 052-756-5981)

**Notice on the non-operating income recorded and the forecast results for the fiscal year ending in March 2022**

Please be advised that, given our recent performances, SUNCORPORATION has decided to make the following revision of its full-year forecasts (April 1, 2021 to March 31, 2022) which was announced on March 15, 2022.

1. Revised performance forecast

(1) Forecast consolidated results for the fiscal year ending in March 2022 (April 1, 2021 - March 31, 2022)

(million yen)

Period	Sales	Operating profits	Ordinary profits	Net profit attributable to the parent company for the fiscal year	Net profit per share for the fiscal year
Forecasts for this time	37,500 – 38,000	1,400 – 1,500	9,300 – 9,900	4,300 – 4,600	179.68 – 192.22yen
Previous forecasts	37,500 – 38,000	1,400 – 1,500	7,500 – 8,000	2,300 – 2,400	92.00 – 98.00 yen
Increase/decrease amount	-	-	1,800 – 1,900	2,000 – 2,200	-
Increase/decrease percentage (%)	-	-	23.8 – 24.0	87.0 – 91.7	-
(Reference) Previous year's results (Fiscal year ended in March 31, 2021)	26,662	687	881	47	2.08 yen

As announced on March 15th in the "Notice on non-operating income", regarding the derivative liabilities recorded in connection with the merger agreement entered into when Cellebrite DI Ltd ("Cellebrite"), a consolidated subsidiary of SUNCORPORATION, became listed on NASDAQ on August 30, 2021, a gain of 4,730,000,000 yen on valuation of derivatives arising from changes in fair value due to changes in Cellebrite's share price and other factors will be recorded as non-operating income. These liabilities affect the Group's results and financial position due to changes in the fair value of Cellebrite's share price and other factors. Therefore, depending on the price movement of Cellebrite's share price in the following term, SUNCORPORATION may record a loss on valuation of derivatives as a non-operating expense due to an

increase in the fair value of the liabilities.

As a side note, the book closing date of the foreign subsidiaries, including Cellebrite, is December 31, 2021. When forecasting the consolidated financial results, we use the financial statements as of the same date, December 31, 2021. As for the material discrepancies in accounting records related to the transactions between consolidated companies, which arise from the book closing date difference, we make the necessary adjustments to consolidate the figures.

(2) Reasons for the revision

Due to the weak-yen trend in the foreign exchange market since the previous announcement on 15 March, a foreign exchange gain of 2,016,000,000 yen is expected in the fourth quarter, which has increased ordinary profits and the net profit attributable to the parent company.

(Notes)

The above forecasts are based on information available as of the date of publication of this document. Actual results may differ from the forecast figures due to various future factors.